Navigation Links
HemoShear to Present Translational Findings from its Vascular and Liver Human Relevant Systems

CHARLOTTESVILLE, Va., Feb. 21, 2013 /PRNewswire/ -- HemoShear LLC, a biotechnology research company and leading developer of human and animal cell-based systems for discovery and assessment of new drug compounds, will present three separate studies from its predictive human relevant systems at The Annual Society of Toxicology (SOT) meeting, being held in San Antonio, Texas, on March 10-14, 2013.  SOT is the world's largest toxicology meeting and is attended by executives and scientists who are responsible for safety assessment of a wide range of drugs, chemicals and materials. 


Each presentation provides evidence of HemoShear's ability to create physiologically accurate vascular or liver conditions that differentiate drug candidates and predict human response at in vivo-level drug doses.

Presentation Information:

DATE: March 12, 2013
ABSTRACT #: 1459
TITLE: Controlled Hemodynamics and Transport in Primary Hepatocytes Shift Induction and Toxic Responses to Drugs Closer to in vivo Concentrations
AUTHORS: Dash A, Deering T, Thomas J, Blackman BR and Wamhoff BR. 

DATE: March 12, 2013
ABSTRACT #: 1216
TITLE: Preclinical Profiling and Computational Differentiation of Human Vascular Response to 95 drugs Using NextGen RNASeq Transcriptomics
AUTHORS: Figler RA, Lawson MJ, Mackey AJ, Berzin EL, Anstey JC, Schoppee-Bortz PD, Tilghman RW, Blackman BR and Wamhoff BR.

DATE:  March 14, 2013
Late Breaking Abstract
TITLE: Human Primary Hepatocytes Under Controlled Hemodynamics Elicit Induction Responses to Drugs at Clinical Cmax Concentrations
AUTHORS: Dash A, Deering T, Marukian S, Thomas J, Blackman BR and Wamhoff BR.  HemoShear collaborator KaLy-Cell, located in Plobsheim France, provided high quality human hepatocytes and biological sample analysis for this program.  KaLy-Cell co-authors include Desbans C, Alexandre E and Richert L.

Drs. Ajit Dash and Brian Wamhoff from HemoShear will attend the SOT meeting.  For more information on the content of HemoShear's abstracts, interested parties may visit the SOT website at

About HemoShear LLC
By applying physiologically accurate hemodynamics and biological transport to primary cell cultures, HemoShear creates human-relevant systems that accurately replicate the biology of organ systems and diseases for applications throughout drug discovery and development. Working in strategic partnerships with pharmaceutical, biotechnology and medical device companies, HemoShear generates meaningful data to increase confidence in decision-making, reduce risk of costly failures and identify efficacious therapies. HemoShear's science leads to new medicines and improves human health.  


Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. HemoShear Relocates and Expands Operations to Historic Martha Jefferson Property in Charlottesville, Virginia
2. HemoShear Adds Industry Veterans Mehmood Khan and Fred Brown to Board of Managers
3. HemoShear Unveils In Vitro Steatosis System at Annual Meeting of the Association for the Study of Liver Diseases
4. HemoShear Publishes Key Review on Human-Relevant Organotypic Systems
5. Masimo to Present at Raymond James 34th Annual Institutional Investors Conference
6. Express Scripts to Present at Upcoming Conferences
7. Actavis, Inc. to Present at the Cowen & Company 33rd Annual Health Care Conference
8. PAREXEL International To Present At Citi Global Healthcare Conference
9. Data Demonstrating the Safety and Efficacy of Chimerixs Antiviral CMX001 Presented at BMT Tandem Meetings
10. Oramed Pharmaceuticals to Present at the 4th Annual Drug Delivery & Formulation Summit in Berlin
11. Dr. Diana Bianchi Presents Data Demonstrating Verinata Healths Proprietary Technology Detects Genetic Abnormalities In Twin Pregnancies
Post Your Comments:
(Date:10/11/2017)... FRISCO, Texas , Oct. 11, 2017 /PRNewswire/ ... healthcare services, has amplified its effort during National ... patients about hereditary cancer risks. ... Journal of Clinical Oncology calculated that more than ... to have inherited mutations in BRCA1 or BRCA2 and ...
(Date:10/5/2017)... , Oct. 5, 2017  In response to ... Oral and Maxillofacial Surgeons (AAOMS) released prescribing recommendations ... to be used as a first-line therapy to ... Recognizing the value ... White Paper "Opioid Prescribing: Acute and Postoperative Pain ...
(Date:10/2/2017)... , Oct. 2, 2017  Eli Lilly and ... financial results for the third quarter of 2017 on ... conference call on that day with the investment community ... The conference call will begin at 9 ... can access a live webcast of the conference call ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... The American Board ... become its next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon ... beginning July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon ...
(Date:10/13/2017)... ... ... Lori R. Somekh, founder of the Law Office of Somekh & ... and special needs planning attorneys. “Membership in ElderCounsel helps our office remain up to ... with elder law attorneys nationwide,” said Somekh. , ElderCounsel was founded ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for ... for action towards gender equality at their inaugural Summit in New York City in ... reached a social audience of over 3 million. To watch the Mobilize Women video, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
Breaking Medicine News(10 mins):